GlobalData’s director of therapy research & analysis in medical devices says the new entity could make an attractive ...

A growing number of companies are dropping their targets following the election of Donald Trump for his second term.

As stores offer empty shelves and locked-up merchandise, the e-commerce giant makes itself convenient to budget-minded shoppers.

Early detection and public health interventions are critical in improving sepsis survival rates and limiting its long-term ...

The pharmaceutical industry is bracing for potentially major disruptions following US President Donald Trump’s announcement ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

Amavita has started using AISAP’s AI-powered POCUS diagnostic in community settings for aortic stenosis screening.

Non-alcoholic options could represent 40% of beer sales in a decade, Big Drop Brewing Co. suggests, arguing the market is “going in one direction”.

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

As the year-end approached, OEMs worked hard to achieve their annual targets, causing the market to heat up, reports Globaldata.

GlobalData said it would launch a 50 million-pound ($62.5 million) buyback program and that it intends to move its listing to the London Stock Exchange's main market from the AIM.

The largest impact will be on Ford's Lincoln Nautilus and General Motors’ Buick Envision, which accounted for 95% of ...